Skip to content
Dose Brief
Menu
No. 100 here · Grade C

Science & Co review

Declares in its own footer that it is not a compounding facility, and explains its own asterisk in its own FAQ — two disclosures most of this market never makes.

Visit Science & Co Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.
Semaglutide
$149/mo month-to-month (compounded)
Tirzepatide
$199/mo month-to-month (compounded)
Coverage
Not published
Brand-name
Compounded only

Prices read from Science & Co's own site on . Providers change pricing without notice — check the current figure before you buy.

On the trackerNewnew to the tracker, no prior reading— New to the tracker on 13 September 2026, read live off the provider's own pages that day rather than taken on trust. There is no earlier reading here to compare against, so the direction is "new" rather than stable — a first observation is not a trend. The reference prices, $149 and $199, are the figures to watch: the advertised $79 and $125 move with them, since the printed discount is computed against the reference.

The scorecard

Science & Co scored on our six Brief Score factors. See the methodology.

Price Stability70/100
Supply Reliability76/100
Transparency82/100
Access Breadth74/100
Clinical Oversight76/100
Track Record76/100

What we like

  • States twice in its footer that "Science and Co, Inc. is not a 503A or 503B compounding facility"
  • Its own FAQ names the commitment behind the headline: "Plans start at $79 a month on the 12 month plan"
  • The printed saving corroborates the reference price — 79 divided by 149 is 53%, exactly the "Save 47%" shown
  • Names its operating entity and state of incorporation, and says every batch is third-party tested

The caveats

  • The number it leads with is a twelve-month commitment; the per-month rates are $149 and $199
  • Only two figures are published per drug, so a three- or six-month plan cannot be priced without starting an intake
  • It says it is not a compounding facility but never names the pharmacy that is
  • Injection only on the pages read, and no brand-name lane

The brief

Best for: A twelve-month committer, or a reader who values a company stating plainly what it is and is not. Declares in its own footer that it is not a compounding facility, and explains its own asterisk in its own FAQ — two disclosures most of this market never makes.

Ranked #100 of 546 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Before you decide

The questions readers ask next after reading about Science & Co.

Closest here

The providers scoring nearest Science & Co — the realistic shortlist if you're weighing it.

Weighing Science & Co against one provider in particular? There is a full head-to-head with our top-ranked pick in CoreAge Rx vs Science & Co, and every provider that outranks it is listed on the Science & Co alternatives ranking.

More providers we track (24)

515 more are filed too — see every provider we track, ranked.

Pricing, states and verification reflect Science & Co's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Science & Co's site. Not medical advice; see our disclosure.

← Back to all rankings